Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

by Sweta Killa

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Company News for Dec 15, 2020

by Zacks Equity Research

Companies In The News Are: BA, ALXN, AZN, CVAC, GOOGL.

Mark Vickery headshot

Vaccines Get to America, but Congressional Relief Lacking

by Mark Vickery

Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down.

Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion

by Zacks Equity Research

Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.

Wall Street Surges on COVID-19 Vaccine Approval

by Zacks Equity Research

Wall Street Surges on COVID-19 Vaccine Approval.

Mark Vickery headshot

Historic Day for Pfizer (PFE), Covid-19 Vaccine

by Mark Vickery

With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.

AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion

by Zacks Equity Research

AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.

Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $120.98, moving +1.78% from the previous trading session.

Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval

by Zacks Equity Research

Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.

Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study

by Zacks Equity Research

Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.

Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag

by Zacks Equity Research

The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.

Should Value Investors Consider Alexion (ALXN) Stock Now?

by Zacks Equity Research

Let's see if Alexion Pharmaceuticals, Inc. (ALXN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection

by Zacks Equity Research

The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q3 Earnings Release?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More

by Zacks Equity Research

Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.

Stock Market News for Oct 30, 2020

by Zacks Equity Research

Wall Street closed higher on Thursday recovering some lost ground of previous day's rout.

Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance

by Zacks Equity Research

Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.

Alexion Pharmaceuticals (ALXN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Alexion (ALXN) delivered earnings and revenue surprises of 25.10% and 11.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Alexion (ALXN) This Earnings Season?

by Zacks Equity Research

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Horizon (HZNP) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.

HCA Healthcare (HCA) Q3 Earnings Miss Estimates, Down Y/Y

by Zacks Equity Research

HCA Healthcare's (HCA) third-quarter results reflect decline in admissions, partly offset by higher revenues.

Trevena (TRVN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.

HCA Healthcare (HCA) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

HCA Healthcare's (HCA) third-quarter 2020 results are likely to reflect higher revenues owing to the gradual rise in patient volumes following the easing of government restrictions.

Alexion Pharmaceuticals (ALXN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.